ProShares Announces Changes to ETF Lineup
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: Business Wire
BETHESDA, Md.--(BUSINESS WIRE)-- ProShares, a premier provider of ETFs, announced today that it plans to close and liquidate the following ETFs based on an ongoing review of ProShares product offerings and client feedback. ProShares ETF Ticker Exchange CDS Short North American HY Credit ETF WYDE Cboe BZX Exchange, Inc. UltraShort Gold Miners GDXS NYSE Arca Ultra Gold Miners GDXX NYSE Arca
Show less
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire
- Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)GlobeNewswire
- Zenas BioPharma to Participate in Upcoming Healthcare Investor ConferencesGlobeNewswire
- Zenas Bio: Recent IPO With Late-Stage Candidate [Seeking Alpha]Seeking Alpha
ZBIO
Sec Filings
- 11/20/24 - Form 4
- 11/12/24 - Form SC
- 11/12/24 - Form 10-Q
- ZBIO's page on the SEC website